Life Sciences

  • July 14, 2026

    Sanofi Says Pfizer, Moderna COVID Jabs Infringe MRNA Tech

    Sanofi's pharmaceutical and therapeutics subsidiaries say the COVID-19 vaccines that have netted Pfizer and Moderna billions of dollars infringe their patents covering mRNA technology, according to a pair of lawsuits filed Tuesday in New Jersey federal court.

  • July 14, 2026

    Patent Eligibility Bill Divides Senators Over Health Costs

    Several U.S. senators expressed strong support at a hearing Tuesday for a bill aimed at expanding which inventions are eligible for patents, while others appeared to have reservations about the potential effect of the proposed changes on healthcare costs.

  • July 14, 2026

    Bayer Defends Fees For Seed Tech With Expired Patents

    Bayer asked a Missouri federal judge to dismiss a sweeping antitrust proposed class action, arguing that the independent seed company suing it, in a complaint that also includes breach of contract allegations, is contesting perfectly legal licensing fees charged for corn technology, even after the last patents expired.

  • July 14, 2026

    Judge Says Vanda-FDA Appointments Fight Likely Ripe

    A D.C. federal judge said he likely had jurisdiction to hear Vanda Pharmaceuticals' latest challenge to the Food and Drug Administration's structure for reviewing new drug applications, but wondered if a recent U.S. Supreme Court decision might doom the company's challenge on the merits.

  • July 14, 2026

    Medical Device Co. Settles FCA Claims

    A company that sells compression devices to reduce swelling in patients with certain medical conditions will pay $551,000 to settle allegations that it obtained Medicare reimbursement with falsified medical records, the U.S. attorney's office in Massachusetts announced Tuesday.

  • July 14, 2026

    CVS Caremark Settles Out Of FTC Suit Over Insulin Pricing

    The Federal Trade Commission reached a settlement on Tuesday with CVS Caremark that includes a number of changes to its business practices, the second deal in a case accusing the country's largest pharmacy benefit managers of inflating insulin prices through unfair rebate schemes.

  • July 14, 2026

    Google Is Wrong, 'Settled Expectations' Is Legal, Justices Told

    Software company VirtaMove has argued that the U.S. Supreme Court should ignore Google's challenge to the U.S. Patent and Trademark Office's policy of using the age of patents as a reason to not review them, saying Google's fight is based on a false foundation.

  • July 14, 2026

    Cayman Judge Orders VC Apple Tree's Management Removed

    A Cayman Islands judge has appointed independent officers to direct Apple Tree Life Sciences Inc., handing a win to a fund tied to a longtime Apple Tree investor that has sought to oust the biotechnology investment company's management as part of a protracted feud.

  • July 14, 2026

    Gov't Shouldn't Face Vax Suit Targeting Moderna, Group Says

    Conservative advocacy organization Eagle Forum Education & Legal Defense Fund on Tuesday urged the Federal Circuit to reject a proposal to shift a multibillion-dollar patent infringement case over the COVID-19 vaccine that is targeting Moderna to the federal government, saying doing so would reduce the crucial economic incentives that power innovation in the pharmaceutical industry.

  • July 14, 2026

    Top Enviro Policy Developments From The First Half Of 2026

    The first half of 2026 saw the repeal of a key rule underlying federal climate regulation, the rollback of pollution limits on industrial chemicals like ethylene oxide, and a blanket exemption from species protections for Gulf oil drillers. Here, Law360 takes a look at the top five developments in environmental policy and regulation so far this year.

  • July 14, 2026

    Goodwin Adds Life Sciences Veteran For San Diego Relaunch

    Goodwin Procter LLP announced on Tuesday that it had hired a veteran life sciences attorney to co-chair its new San Diego office, which is slated to open later this summer.

  • July 14, 2026

    AI Drug Discovery Biz Valued At $3.8B After Series C Round

    Artificial intelligence-based drug discovery company Chai Discovery on Tuesday revealed that it reached a $3.8 billion valuation after closing its latest funding round with $400 million in tow.

  • July 14, 2026

    BakerHostetler Flips Holland & Knight's Antitrust Co-Lead

    An attorney with nearly 25 years of experience in commercial and antitrust litigation has moved his practice to BakerHostetler's Philadelphia office after five years with Holland & Knight LLP.

  • July 14, 2026

    States Will Get $18M From 23andMe Ch. 11 For Data Breach

    A week after a bankruptcy court approved a $46.75 million settlement between the DNA testing company 23andMe and data breach claimants, a coalition of more than 40 states announced Tuesday that they would share in an additional $18 million to resolve claims of unreasonable security practices.

  • July 14, 2026

    Pharma Cos. Clash In Del. Chancery Over Dental Drug License

    Ventis Pharma Inc. has sued Balanced Pharma Inc. in the Delaware Chancery Court, accusing its licensee of failing to make commercially reasonable efforts to develop and market a licensed dental anesthetic product and seeking a declaration that the companies' exclusive licensing agreement has been terminated.

  • July 13, 2026

    Albertsons, Safeway Face Trial Over Wash.'s Opioid Epidemic

    Albertsons and Safeway ignored signs of problematic opioid prescriptions in Washington for years, an attorney for the state told a Seattle judge Monday during opening statements in a bench trial over allegations that the pharmacy chains failed to prevent the diversion of opioids that fueled the state's long-running overdose crisis.

  • July 13, 2026

    2nd Circ. Says Tylenol Maker Must Face Autism, ADHD Suits

    The Second Circuit said Monday that a lower court had wrongly excluded plaintiffs experts from testifying about an alleged relationship between using Tylenol during pregnancy and autism spectrum disorder and attention-deficit/hyperactivity disorder, although the panel cautioned that the decision was not political or scientific.

  • July 13, 2026

    FTC Secures $12M Settlement Over Edwards-JC Medical Deal

    California-based Edwards Lifesciences and Singapore's Genesis Medtech agreed to pay a combined $12 million to settle claims from the Federal Trade Commission that Edwards attempted to evade the Hart-Scott-Rodino notification and waiting period when it acquired medical device maker JC Medical from Genesis in 2024.

  • July 13, 2026

    CVS Toddler Wipes Mislabeled As Hypoallergenic, Suit Says

    CVS customers hit the pharmacy retail giant with a proposed false advertising class action in California federal court alleging that its "Ultra-Soft Toddler Cleansing Wipes" are deceptively labeled as being hypoallergenic, since they are formulated with added fragrance, a cosmetic allergen that serves no functional skin care purpose.

  • July 13, 2026

    7th Circ. Revives Teva Suit Over Eli Lilly Generic Drug Block

    The Seventh Circuit on Monday revived a breach-of-contract lawsuit against Eli Lilly, ruling that an earlier legal settlement under which Eli Lilly agreed not to block the approval and marketing of Teva Pharmaceuticals' generic version of its osteoporosis drug Forteo didn't necessarily expire when the underlying patents did.

  • July 13, 2026

    23andMe Bankruptcy Plan Bars Data Breach Suit In Calif.

    A Missouri bankruptcy judge has told attorneys representing California the state can no longer press its data breach lawsuit against the reorganized 23andMe, finding the state court action is barred by the company's confirmed Chapter 11 plan.

  • July 13, 2026

    Assertio Beats Investor Suit Over Drug, Merger Claims

    An Illinois federal judge Friday dismissed a proposed investor class action claiming Assertio misled shareholders about threats to sales of its arthritis drug Indocin, saying the company's public filings explicitly and repeatedly warned that the drug lacked patent protection and faced imminent generic competition at any time.

  • July 13, 2026

    Families Cite Geofence Ruling In Newborn Blood Testing Case

    A group of parents suing the state of Michigan over the way newborn blood samples are collected and stored has asked a federal judge to revive its claims by citing recently decided U.S. Supreme Court precedent over the use of bulk cellphone data by police.

  • July 13, 2026

    Catching Up With Delaware's Chancery Court

    The Delaware Chancery Court last week handled disputes involving corporate control, post-closing competition, executive departures, arbitration awards and shareholder litigation.

  • July 13, 2026

    Health Org. Can't Halt FTC Texas Suit Over Trans Youth Care

    A D.C. federal court declined to bar the Federal Trade Commission from pursuing a consumer protection suit in Texas against the World Professional Association for Transgender Health, finding WPATH failed to show those proceedings threatened the court's injunction of a related investigation by the FTC.

Expert Analysis

  • How 'Spillover' Effects Can Skew AI Securities Class Actions

    Author Photo

    Event study evidence is often central in securities litigation at class certification and beyond, but in an environment where earnings forecasts and statements can have spillover market implications, particularly when concerning artificial intelligence, the task of parsing out the price impact of news requires careful consideration, say Erik Johannesson, Olivia Wurgaft and Nguyet Nguyen at Brattle Group.

  • Previewing FDA National Priority Vouchers In Psychedelics EO

    Author Photo

    President Donald Trump's recent executive order on psychedelic drug access represents a watershed moment in federal drug policy, but its significance lies in two distinct regulatory pathways, the first being the Commissioner's National Priority Vouchers, which offer a significant opportunity to compress U.S. Food and Drug Administration review, say Kimberly Chew at Husch Blackwell and Odette Hauke at Odette Alina.

  • Series

    Playing Magic: The Gathering Makes Me A Better Lawyer

    Author Photo

    The competitive card game Magic: The Gathering offers me a training ground for the strategic thinking skills crucial to litigation, challenging me to adapt to oft-updated rules, analyze text as complicated as any statute and anticipate my opponent’s next moves, says Christopher Smith at Lash Goldberg.

  • Why Product-Based Public Nuisance Claims May Be Waning

    Author Photo

    The Maryland Supreme Court's recent decision in Express Scripts v. Anne Arundel County is the latest in a national trend of rulings rejecting product-based public nuisance claims — but other forms of government litigation against companies that allegedly increase the cost of public services are likely to continue, say attorneys at Simpson Thacher.

  • Improving Well-Being In Law, 10 Years After Landmark Study

    Author Photo

    An important 2016 study revealed significant substance abuse and mental health issues among lawyers, and while the findings helped normalize the conversation around these topics, a decade later, structural change is still needed, says Denise Robinson at PLI.

  • How To Gear Up For Trump's Pharma Tariffs

    Author Photo

    President Donald Trump's proclamation establishing tariffs on certain pharmaceutical products holds a few areas of ambiguity that companies should review and prepare for before the tariffs come into effect later this year, say attorneys at Arnold & Porter.

  • How The Coming Months Will Shape State Drug Price Boards

    Author Photo

    The future of state prescription drug affordability boards may be determined in the next few months, between an upcoming court decision in a challenge against state authority to set drug prices, and pending state decisions about whether to use federal Medicare maximum fair prices as reference, say Michael Kolber, Steven Chen and Kelechi Ezealaji at Manatt.

  • High Court 'Skinny Label' Case Will Matter To Tech Litigators

    Author Photo

    Hikma v. Amarin, set for oral argument in the U.S. Supreme Court on Wednesday, has potential to affect not just generic drug label-based evidence in patent cases, but also how technology inducement cases are presented and proven, says attorney Abdul Abdullahi.

  • How Food, Beverage Claims May Preview Cosmetic Litigation

    Author Photo

    Class action litigation targeting cosmetics and personal care products is accelerating, with a playbook that comes from the food and beverage industry — and the defenses that succeeded, and failed, in past class actions offer a critical road map for beauty and personal care brands, say attorneys at Crowell.

  • Court's HRSA Policy Reversal Leaves 340B Rules Murky

    Author Photo

    A D.C. federal court's recent decision in Premier v. U.S. Department of Health limits the Health Resources and Services Administration's ability to enforce long-standing Section 340B interpretations through subregulatory guidance, leaving open core statutory questions about purchasing models, inventory classification and program oversight, says Martha Cramer at Hooper Lundy.

  • Series

    Officiating Football Makes Me A Better Lawyer

    Author Photo

    Though they may seem to have little in common, officiating football has sharpened many of the same skills that define effective lawyering in management-side labor and employment: preparation, judgment, composure, credibility and ability to make difficult decisions in real time, says Josh Nadreau at Fisher Phillips.

  • Fresenius Ruling May Shift Anti-Kickback Enforcement

    Author Photo

    The Ninth Circuit's recent decision in Fresenius v. Bonta suggests that businesses have a First Amendment right to donate to certain charities, even if those donations are motivated by economic self-interest, potentially calling into question years of Anti-Kickback Statute proceedings against pharmaceutical manufacturers for making similar donations, says Jonah Knobler at Patterson Belknap.

  • Written Consent Ruling May Signal Change For Telemarketing

    Author Photo

    The Fifth Circuit's ruling in Bradford v. Sovereign Pest Control is a takedown of the Federal Communications Commission's prior express written consent regulation, and because Loper Bright empowers courts to disregard agency interpretations, Telephone Consumer Protection Act litigants now have an opportunity to challenge previously settled FCC regulations, orders and interpretations, say attorneys at Manatt.

  • Series

    Law School's Missed Lessons: How To Draft Pleadings

    Author Photo

    Most law school graduates step into their first jobs without ever having drafted a complaint, answer, motion or other type of pleading, but that gap can be closed by understanding the strategy embedded in every filing, writing with clarity and purpose, and seeking feedback at every step, says Eric Yakaitis at Haug Barron.

  • At The Fed. Circ., Means-Plus-Function Is Not Quite Dead

    Author Photo

    Recent Federal Circuit opinions confirm that means-plus-function claims continue to be drafted, issued, litigated and even infringed — but minding the restrictions imposed over the years by courts and statute requires three steps, says Jay Yates at Patterson & Sheridan.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.